Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

canakinumab × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1

Interventions

Specimen Handling 374 pembrolizumab 306 Magnetic Resonance Spectroscopy 306 Biopsy 237 Carboplatin 212 Cyclophosphamide 196 Cisplatin 172 Paclitaxel 157 Nivolumab 146 Gemcitabine 133 Radiotherapy 129 venetoclax 119 Bevacizumab 113 Dexamethasone 109 fludarabine 96 Rituximab 90 Fluorouracil 90 Pemetrexed 89 Oxaliplatin 88 durvalumab 87 Doxorubicin 86 Docetaxel 84 atezolizumab 82 Radiation 80 Prednisone 79 Lenalidomide 76 Ipilimumab 69 X-Rays 67 Leucovorin 66 Capecitabine 66

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06038526 2026-02-19

Evaluation of Canakinumab in High-Risk Former-Smokers

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡